Skip to main content
CSPC Pharmaceutical Group Limited logo

CSPC Pharmaceutical Group Limited — Investor Relations & Filings

Ticker · 1093 ISIN · US12591J1088 LEI · 529900M3XQCW234H8O91 HKEX Manufacturing
Open in API
Filings indexed 1,523 across all filing types
Latest filing 2021-06-01 Regulatory Filings
Country HK Hong Kong
Listing HKEX 1093

About CSPC Pharmaceutical Group Limited

https://www.cspc.com.hk/en/global/home.…

CSPC Pharmaceutical Group Limited is a comprehensive enterprise specializing in the research, development, manufacturing, and sale of pharmaceutical products. The company operates across two main segments: finished drugs and bulk drugs. It emphasizes innovation and new drug development, evidenced by substantial R&D investment, to produce high-quality, effective, and reliable medicines. Its portfolio includes key innovative products such as NBP (soft capsules and injections), Oulaining, and Enxi, which are among its top-selling drugs.

Recent filings

Filing Released Lang Actions
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 31 MAY 2021
Regulatory Filings Classification · 95% confidence The document is titled 'Monthly Return of Equity Issuer on Movements in Securities' for the month ended 31/05/2021, submitted to the Hong Kong Exchanges and Clearing Limited. It details movements in authorised share capital, issued share capital, share options, warrants, convertibles, and other share-related transactions. The content focuses on share capital changes and confirmations related to securities issued during the month. There are no financial statements, earnings data, management discussion, or audit information. The document is a regulatory filing reporting share capital movements and confirmations to the stock exchange, typical of a regulatory compliance report rather than a financial report or announcement of a report. It is not a report publication announcement since it contains substantive data on share capital movements. Therefore, the most appropriate classification is Regulatory Filings (RNS).
2021-06-01 English
VOLUNTARY ANNOUNCEMENT - "LACOSAMIDE TABLETS" OBTAINS DRUG REGISTRATION APPROVAL
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by CSPC Pharmaceutical Group Limited regarding the drug registration approval of a product called "Lacosamide Tablets." It is a short announcement (2524 characters) that informs about regulatory approval and product details. There is no financial data, no mention of financial results, no meeting materials, no voting results, no management changes, no legal proceedings, no capital changes, and no detailed report or presentation. The document is clearly an announcement of a regulatory approval event, not a financial or governance report. Given the short length and nature of the content, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2021-05-31 English
VOLUNTARY ANNOUNCEMENT - HIGHLY SELECTIVE CDK9 INHIBITOR "SYHX1903" OBTAINS CLINICAL TRIAL APPROVAL IN CHINA
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors of CSPC Pharmaceutical Group Limited regarding the clinical trial approval of a new drug product. It is an announcement of a regulatory milestone and does not contain financial statements, detailed financial analysis, or management discussion of financial results. The document is relatively short (2571 characters) and serves as a news update rather than a formal report or filing. It does not fit categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a regulatory filing in the sense of compliance documents or certifications, nor is it a governance or remuneration report. The content is about a clinical trial approval, which is a significant corporate announcement but not related to financing, mergers, or shareholding changes. Therefore, the best fitting category is Regulatory Filings (RNS), which is the fallback for miscellaneous regulatory announcements that do not fit other specific categories.
2021-05-25 English
VOLUNTARY ANNOUNCEMENT - "LINAGLIPTIN TABLETS" OBTAINS DRUG REGISTRATION APPROVAL
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by CSPC Pharmaceutical Group Limited regarding the approval of a new drug product, Linagliptin Tablets, by the National Medical Products Administration of China. It is a short announcement (2354 characters) that informs the market about a regulatory milestone related to the company's product portfolio. There are no financial statements, no detailed financial analysis, no meeting materials, no voting results, no management discussion, no earnings data, and no mention of any report being attached or published. The content is clearly an announcement of a corporate event related to product approval, which does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is not a regulatory filing in the sense of compliance documents or certifications, but rather a voluntary corporate announcement. Given the filing definitions, this type of document best fits under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2021-05-25 English
VOLUNTARY ANNOUNCEMENT - NBL-015 OBTAINS CLINICAL TRIAL APPROVAL IN THE U.S.
Regulatory Filings Classification · 95% confidence The document is a voluntary announcement by the board of directors of CSPC Pharmaceutical Group Limited regarding the approval of a clinical trial application (IND) by the U.S. FDA for a drug candidate NBL-015. It is a short announcement (3025 characters) that provides news about a regulatory milestone related to drug development. There are no financial statements, no detailed financial data, no meeting materials, no voting results, no management discussion, no audit information, and no regulatory certifications. The document is not a report but an announcement of a significant event. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Management Reports. It is not a regulatory filing in the sense of compliance documents or certifications. It is a voluntary announcement about a clinical trial approval, which is best classified under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2021-05-25 English
QUARTERLY RESULTS FOR THE THREE MONTHS ENDED 31 MARCH 2021
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Quarterly Results For the three months ended 31 March 2021' and contains detailed unaudited financial statements including condensed consolidated statements of profit or loss, segment revenue and profit, earnings per share, and business review commentary. It covers a fiscal period shorter than a full year (quarterly) and includes substantive financial data and analysis. The presence of detailed financial tables and segment analysis confirms it is a comprehensive interim financial report rather than a brief announcement or a certification. Therefore, the document fits the definition of an Interim / Quarterly Report (IR). Q1 2021
2021-05-24 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.